NEW ORLEANS -- The benefit of mavacamten (Camzyos) held up in symptomatic adolescents with obstructive hypertrophic cardiomyopathy (HCM), the phase III SCOUT-HCM trial showed. Already available to ...
Background. A 61-year-old man presented with shortness of breath and chest pain on exertion. He had been diagnosed as having hiatus hernia 2 years previously and was taking proton-pump inhibitors as ...
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results